This Article Full Text (PDF) All Versions of this Article: 1087057107300464v1 12/4/464    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Web of Science (2) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Uvebrant, K. Articles by Björk, P. Search for Related Content PubMed PubMed Citation Articles by Uvebrant, K. Articles by Björk, P. Social Bookmarking                         What's this?

Discovery of Selective Small-Molecule CD80 Inhibitors

Active Biotech Research AB, Lund, Sweden, CRG, University Hospital, Malmö, Sweden

Dorthe Da Graça Thrige

Active Biotech Research AB, Lund, Sweden

Anna Rosén

Alligator Bioscience AB, Lund, Sweden

Mats Åkesson

Wieslab AB, Lund, Sweden

Helena Berg

Acadia Pharmaceuticals AB, Malmö, Sweden

Björn Walse

SARomics AB, Lund, Sweden

Per Björk

Active Biotech Research AB, Lund, Sweden, per.bjork{at}activebiotech.com

Protein-protein interactions are widely found in biological systems controlling diverse cellular events. Because these interactions are implicated in many diseases such as autoimmunity and cancer, regulation of protein-protein interactions provides ideal targets for drug intervention. The CD80-CD28 costimulatory pathway plays a critical role in regulation of the immune response and thus constitutes an attractive target for therapeutic manipulation of autoimmune diseases. The objective of this study is to identify small compounds disrupting these pivotal protein-protein interactions. Compounds that specifically blocked binding of CD80 to CD28 were identified using a strategy involving a cell-based scintillation proximity assay as the initial step. Secondary screening (e.g., by analyzing the direct binding of these compounds to the target immobilized on a biosensor surface) revealed that these compounds are highly selective CD80 binders. Screening of structurally related derivatives led to the identification of the chemical features required for inhibition of the CD80-CD28 interaction. In addition, the optimization process led to a 10-fold increase in binding affinity of the CD80 inhibitors. Using this approach, the authors identify low-molecular-weight compounds that specifically and with high potency inhibit the interaction between CD80 and CD28. These compounds serve as promising starting points for further development of CD80 inhibitors as potential immunomodulatory drugs. (Journal of Biomolecular Screening 2007:464-472)

Key Words: drug discovery • protein-protein interaction • screening assay • costimulation • inhibitors

This version was published on June 1, 2007

Journal of Biomolecular Screening, Vol. 12, No. 4, 464-472 (2007)
DOI: 10.1177/1087057107300464


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?